BPC-157 for Esophageal Damage: Acid Reflux Injury Research

BPC-157 GI

Sphincter Recovery

In rat models of chronic esophagitis, BPC-157 restored lower esophageal sphincter pressure and healed esophageal lesions that persisted for months after sphincter failure.

Petrovic et al., Journal of Pharmacological Sciences, 2006

Petrovic et al., Journal of Pharmacological Sciences, 2006

View as image

Gastroesophageal reflux disease (GERD) affects an estimated 20% of adults in Western countries, and chronic acid exposure damages the esophageal mucosa, causing erosive esophagitis, strictures, and in some cases Barrett's esophagus, a precancerous condition. Standard treatments, proton pump inhibitors (PPIs) and H2 blockers, reduce acid production but do not directly heal damaged tissue or address sphincter dysfunction. BPC-157, the gastric pentadecapeptide originally isolated from human gastric juice, has been tested in several rat models of esophageal damage with results that suggest tissue-protective and sphincter-restoring effects.^[1] This article reviews every published preclinical study on BPC-157 and esophageal injury. For the broader BPC-157 evidence landscape, see The Real BPC-157 Story.

The Sphincter Failure Model

The most directly relevant studies for acid reflux use a rat model where chronic esophagitis is created by surgically inducing sphincter dysfunction. Understanding this model matters because it determines how applicable the findings are to human GERD.

Petrovic et al. (2006): The Foundational Study

Petrovic et al. created prolonged esophagitis in rats by suturing small tubes into both the lower esophageal sphincter (LES) and the pyloric sphincter.^[2] This produced persistent sphincter failure with continuously lowered pressure in both sphincters, resulting in chronic reflux of gastric contents into the esophagus. The esophageal damage was severe: confluent hemorrhagic and yellowish lesions, thinned epithelium, loss of the superficial corneal layer, and disorganized stratification.

BPC-157 was administered either intraperitoneally (10 mcg/kg) or continuously in drinking water (10 mcg/kg/day). The results:

Macroscopic healing: BPC-157-treated rats showed reduced esophageal lesion severity compared to controls, with less hemorrhagic damage and improved mucosal appearance.

Sphincter pressure restoration: BPC-157 increased pressure in both the LES and pyloric sphincter. This is a distinctive finding because most anti-reflux medications (PPIs, H2 blockers) reduce acid production without addressing the underlying mechanical problem of sphincter incompetence. If BPC-157 genuinely restores sphincter tone, it would represent a different therapeutic approach than acid suppression.

Microscopic improvement: Treated groups showed fewer polymorphonuclear and mononuclear inflammatory cells across all assessed time periods, indicating reduced tissue inflammation.

Dobric et al. (2007): Pyloric Sphincter Primary Dysfunction

Dobric et al. used a variation of the model where only the pyloric sphincter was disrupted, creating prolonged esophagitis through retrograde flow.^[3] BPC-157 again demonstrated therapeutic potential, reducing esophagitis severity and improving sphincter function. This study confirmed that BPC-157's effects were not limited to LES dysfunction models and suggested the peptide could address esophageal damage regardless of which sphincter was the primary source of failure.

Petrovic et al. (2011): Sphincter Failure-Esophagitis-Pancreatitis Connection

A later study from the same group extended the model to examine the relationship between sphincter failure, esophagitis, and secondary pancreatitis.^[4] In rats with surgically induced sphincter dysfunction, esophagitis developed alongside pancreatic injury. BPC-157 administration addressed both the esophagitis and the pancreatic damage, suggesting the peptide's effects extended to the entire upper GI sphincter system. This study also included a small clinical observation: acute pancreatitis patients showed low sphincter pressures, providing a human correlate to the rat model, though BPC-157 was not tested in these patients.

The Cytoprotection Comparison

Sikiric et al. (1999): BPC-157 vs. Ranitidine, Sucralfate, and Cholestyramine

One of the most informative studies compared BPC-157's cytoprotective effects against three established anti-reflux agents in a rat reflux esophagitis model.^[5]

The agents tested:

• BPC-157 (10 mcg/kg intraperitoneally)
• Ranitidine (H2 receptor antagonist, the standard comparison)
• Sucralfate (mucosal protectant)
• Cholestyramine (bile acid sequestrant)

All four agents showed cytoprotective activity against reflux esophagitis. The key finding was that BPC-157's protective effect was more sustained over time compared to the other agents. While ranitidine and sucralfate provided initial protection, BPC-157's effects appeared to have a longer duration of action in this model.

This study is notable because it used established medications as comparators, which is uncommon in BPC-157 research. The comparison provides a reference frame for BPC-157's effect size, though the study did not report whether the differences between agents reached statistical significance in a pre-specified analysis.

Surgical and Fistula Models

Esophagogastric Anastomosis Healing

Djakovic et al. (2016) tested BPC-157 in rats after esophagogastric anastomosis (surgical reconnection of the esophagus to the stomach).^[6] This model is clinically relevant to patients who undergo esophageal surgery for cancer, strictures, or other conditions.

BPC-157 improved anastomotic healing. The study also tested L-arginine (a nitric oxide precursor) and L-NAME (a nitric oxide synthase inhibitor). L-arginine improved healing similarly to BPC-157, while L-NAME aggravated it. When BPC-157 and L-NAME were given together, BPC-157 counteracted L-NAME's deleterious effects. This provides evidence that BPC-157's esophageal healing effects operate at least partially through the nitric oxide pathway, consistent with its documented interaction with the Src-Caveolin-1-eNOS signaling cascade in other tissues.^[7]

Esophagocutaneous Fistula

Cesarec et al. (2013) tested BPC-157 in rats with esophagocutaneous fistulas, abnormal connections between the esophagus and skin surface.^[8] BPC-157 promoted fistula closure when given intraperitoneally or intragastrically. This study extends BPC-157's esophageal healing data beyond reflux-type damage to structural defects, though esophagocutaneous fistulas are rare clinical entities.

NSAID-Induced Sphincter Damage

Vitaic et al. (2017) examined a clinically relevant scenario: NSAID-induced sphincter failure.^[9] Non-steroidal anti-inflammatory drugs like diclofenac are known to damage the gastrointestinal tract, and this study showed they also impair esophageal and pyloric sphincter function in rats. BPC-157 counteracted the NSAID-induced sphincter dysfunction.

This finding has particular relevance because NSAID use is extremely common, and NSAID-associated upper GI damage (including esophageal injury) represents a significant clinical burden. If BPC-157 could protect sphincter function during NSAID therapy, it would address a gap that current co-prescribing strategies (like PPIs with NSAIDs) only partially fill.

Park et al. (2020) further demonstrated that BPC-157 rescued NSAID-induced cytotoxicity by stabilizing intestinal permeability and enhancing cytoprotection.^[10] While this study focused on intestinal rather than esophageal tissue, it reinforces the cytoprotective mechanism that appears to operate throughout the GI tract, including the esophagus.

Cytoprotection: Where the Esophageal Data Fits

BPC-157's esophageal effects are part of a broader cytoprotective pattern that spans the entire gastrointestinal tract. The concept of cytoprotection, introduced by Andre Robert in the 1970s, describes the ability of certain agents to protect mucosal tissue from injury independent of acid suppression. Robert demonstrated that prostaglandins could prevent gastric lesions even without reducing acid output. Sikiric's group has positioned BPC-157 as a next-generation cytoprotective agent that extends Robert's concept.

Sikiric et al. (2020) published a comprehensive review of BPC-157 as an extension of Robert's cytoprotection framework, documenting protective effects across the stomach, duodenum, small intestine, colon, and esophagus.^[7] The esophageal data fits within this pattern: BPC-157 appears to protect mucosal tissue from diverse insults (acid, bile, NSAIDs, surgical trauma) through mechanisms that do not depend on acid suppression.

This framing matters because it suggests BPC-157's esophageal effects are not esophagus-specific but rather a local manifestation of a system-wide cytoprotective action. The same peptide protects against gastric ulcers, NSAID-induced intestinal damage, and colitis in animal models. Whether this generalized cytoprotection translates to clinical utility for any specific GI condition remains unproven.

Proposed Mechanisms for Esophageal Protection

BPC-157's effects on esophageal tissue appear to involve at least three converging mechanisms:

Nitric oxide pathway modulation. The Djakovic 2016 study directly demonstrated NO dependence of esophageal healing effects. BPC-157's interaction with the eNOS pathway promotes vasodilation, improved blood flow, and tissue repair. This aligns with broader BPC-157 mechanistic data showing Src-Caveolin-1-eNOS activation across multiple tissue types.

Cytoprotective signaling. Sikiric et al. (2018) positioned BPC-157 as a "novel cytoprotective mediator" that promotes vascular recruitment and protects mucosal integrity.^[1] In the esophagus, this would protect the epithelium from acid and bile exposure, reduce inflammatory cell infiltration, and accelerate mucosal regeneration. The cytoprotective concept ties together BPC-157's effects on epithelial cells, inflammatory mediators, and tissue vascularity into a unified framework, though each component has been studied in isolation rather than as an integrated pathway.

Direct sphincter tone effects. Multiple studies documented BPC-157's ability to increase LES and pyloric sphincter pressure. The mechanism for this sphincter effect is poorly understood but may involve modulation of the enteric nervous system or direct effects on smooth muscle contractility. This is distinct from prokinetic agents like metoclopramide, which also increase LES pressure but through dopamine receptor antagonism. The sphincter effect is particularly interesting because it addresses the root mechanical cause of reflux rather than just its chemical consequences.

What remains unknown is whether BPC-157 acts on a specific receptor in esophageal tissue. The peptide's receptor has not been identified in any tissue, and without this information, the signaling pathway from BPC-157 binding to sphincter pressure changes remains a black box. This is the single largest obstacle to understanding how BPC-157 works in the esophagus or anywhere else.

Limitations and Missing Evidence

Single research group. Every esophageal BPC-157 study originated from the Zagreb group or close collaborators. Independent replication is absent. A 2025 review noted this concentration of evidence as a limitation across the entire BPC-157 literature.^[11]

Surgical models vs. human GERD. The rat models use surgically implanted tubes to create sphincter failure. Human GERD involves transient LES relaxations, hiatal hernia, and multifactorial sphincter dysfunction, not mechanical obstruction. Whether BPC-157's sphincter-restoring effects in surgically disrupted rats translate to the more subtle dysfunction of human GERD is unknown.

No dose-response data. Most studies used a single dose (10 mcg/kg) or the standard two-dose comparison (10 mcg/kg and 10 ng/kg). Proper dose-response curves for esophageal endpoints have not been published.

No long-term safety data. Chronic GERD treatment requires long-term therapy (many patients take PPIs for years). BPC-157's safety with prolonged administration has not been evaluated, even in animals.

Zero human trials. No clinical trial has tested BPC-157 for GERD, esophagitis, Barrett's esophagus, or any esophageal condition. The newest preclinical updates continue to produce positive results,^[12] but the translation gap remains absolute. The ghost trial of BPC-157 for ulcerative colitis, which was registered but never reported results, illustrates the broader challenge of moving BPC-157 from animal data to human evidence.

No Barrett's esophagus data. None of the animal studies examined whether BPC-157 affects metaplastic or dysplastic tissue. Barrett's esophagus, a precancerous consequence of chronic GERD, involves replacement of squamous epithelium with columnar epithelium. Whether BPC-157's cytoprotective and angiogenic effects would benefit or potentially harm metaplastic tissue is unknown. Given the theoretical cancer risk concerns associated with BPC-157's pro-angiogenic properties, this question would need to be addressed before any clinical application in chronic GERD patients who may harbor occult Barrett's changes.

For broader context on BPC-157's gastrointestinal evidence, its proposed gut-protective mechanisms, the question of oral stability, and its potential role in inflammatory bowel disease, see the related articles in this cluster. The BPC-157 leaky gut research addresses the intestinal permeability dimension of BPC-157's GI effects.

The Bottom Line

BPC-157 has shown consistent esophageal protective effects across multiple rat studies, including reduced esophagitis severity, restored sphincter pressure, accelerated anastomotic healing, and sustained cytoprotection that outperformed ranitidine in one comparative study. These effects appear to operate through nitric oxide pathway modulation and broader cytoprotective mechanisms. All evidence comes from preclinical models using surgically induced sphincter failure, and no human clinical trials have been conducted for any esophageal application.

Frequently Asked Questions

Can BPC-157 help with acid reflux?

In rat models, BPC-157 reduced esophagitis caused by acid reflux and restored lower esophageal sphincter pressure (Petrovic et al., 2006). It also outperformed ranitidine in sustaining cytoprotective effects in a reflux esophagitis model (Sikiric et al., 1999). No human clinical trials have tested BPC-157 for acid reflux or GERD.

Does BPC-157 heal esophageal damage?

In rats with surgically induced chronic esophagitis, BPC-157 reduced hemorrhagic lesions, thinned epithelium damage, and inflammatory cell infiltration. It also promoted healing of esophagogastric anastomoses and esophagocutaneous fistulas. All findings are from preclinical animal studies with no human confirmation.

How does BPC-157 affect the lower esophageal sphincter?

Multiple rat studies documented BPC-157 increasing lower esophageal sphincter (LES) pressure after surgical disruption. This is different from acid-suppressing drugs, which reduce acid but do not address sphincter dysfunction. The mechanism is not fully understood but appears to involve nitric oxide pathway modulation (Djakovic et al., 2016).

Is BPC-157 better than PPIs for GERD?

No study has compared BPC-157 to proton pump inhibitors. One rat study compared BPC-157 to ranitidine (an H2 blocker) and found BPC-157 had more sustained cytoprotective effects. PPIs and BPC-157 work through entirely different mechanisms: PPIs suppress acid production, while BPC-157 appears to protect tissue and restore sphincter tone. No human comparison data exists.

Can you take BPC-157 orally for esophageal healing?

Several rat studies administered BPC-157 intragastrically (orally) and found esophageal healing effects, suggesting oral administration reaches the esophageal tissue. BPC-157 is stable in gastric acid, which is unusual for a peptide. No human oral dosing studies for esophageal conditions have been published.

Are there human trials of BPC-157 for esophagitis?

No. As of 2026, zero human clinical trials have tested BPC-157 for esophagitis, GERD, Barrett's esophagus, or any esophageal condition. All published evidence comes from rat models with surgically induced sphincter dysfunction, which differs from the mechanism of human GERD.